K.R. Hunter

1.3k total citations · 1 hit paper
20 papers, 847 citations indexed

About

K.R. Hunter is a scholar working on Neurology, Organic Chemistry and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, K.R. Hunter has authored 20 papers receiving a total of 847 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 3 papers in Organic Chemistry and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in K.R. Hunter's work include Parkinson's Disease Mechanisms and Treatments (9 papers), Neurological disorders and treatments (5 papers) and Neurological and metabolic disorders (3 papers). K.R. Hunter is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (9 papers), Neurological disorders and treatments (5 papers) and Neurological and metabolic disorders (3 papers). K.R. Hunter collaborates with scholars based in United Kingdom, Jamaica and United States. K.R. Hunter's co-authors include G M Stern, M. Sandler, Laurence Després, Jeremy Chataway, P. Armitage, Casper Nielsen, Nadine Schuerer, Ali Alsanousi, Nick C. Fox and Chris Frost and has published in prestigious journals such as Nature, The Lancet and Neurology.

In The Last Decade

K.R. Hunter

20 papers receiving 786 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

2014 304 citations Jeremy Chataway, Nadine Schuerer et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K.R. Hunter United Kingdom	11	272	222	195	189	96	20	847
P.-A. Löschmann Germany	12	211 0.8×	67 0.3×	287 1.5×	294 1.6×	49 0.5×	19	822
Yukio Nishizawa Japan	13	73 0.3×	113 0.5×	461 2.4×	390 2.1×	26 0.3×	27	1.4k
Sowmya Chollate United States	6	152 0.6×	420 1.9×	62 0.3×	650 3.4×	101 1.1×	6	1.3k
Satoe Shimoda‐Matsubayashi Japan	8	157 0.6×	34 0.2×	116 0.6×	385 2.0×	48 0.5×	9	725
Teruyoshi Inoue Japan	18	100 0.4×	36 0.2×	231 1.2×	442 2.3×	103 1.1×	40	1.0k
Jochen C. Ulzheimer Germany	10	60 0.2×	65 0.3×	226 1.2×	298 1.6×	30 0.3×	11	1.2k
A Rostock Germany	10	45 0.2×	58 0.3×	421 2.2×	475 2.5×	87 0.9×	20	1.1k
Shi-Du Yan United States	9	195 0.7×	73 0.3×	152 0.8×	590 3.1×	20 0.2×	10	1.3k
Nathalie Pizzinat France	19	90 0.3×	70 0.3×	224 1.1×	592 3.1×	26 0.3×	36	1.2k
Daniel Durán United States	15	284 1.0×	79 0.4×	311 1.6×	386 2.0×	48 0.5×	29	1.3k

Countries citing papers authored by K.R. Hunter

Since Specialization

Citations

This map shows the geographic impact of K.R. Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.R. Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.R. Hunter more than expected).

Fields of papers citing papers by K.R. Hunter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.R. Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.R. Hunter. The network helps show where K.R. Hunter may publish in the future.

Co-authorship network of co-authors of K.R. Hunter

This figure shows the co-authorship network connecting the top 25 collaborators of K.R. Hunter. A scholar is included among the top collaborators of K.R. Hunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.R. Hunter. K.R. Hunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chataway, Jeremy, Nadine Schuerer, Ali Alsanousi, et al.. (2014). Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet. 383(9936). 2213–2221. 304 indexed citations breakdown →

Chataway, Jeremy, Nadine Schuerer, Ali Alsanousi, et al.. (2013). THE MS-STAT TRIAL: High Dose Simvastatin Slows Brain Atrophy and Delays Disability in Secondary Progressive Multiple Sclerosis: A Phase II Placebo-Controlled Trial (PL02.001). Neurology. 80(7_supplement). 6 indexed citations

Heap, Marion, Julian Bion, & K.R. Hunter. (1989). Miliary tuberculosis and the adult respiratory distress syndrome. Respiratory Medicine. 83(2). 153–156. 10 indexed citations

Hunter, K.R.. (1977). JAMES PARKINSON (1755–1824): A LESSON FOR CLINICAL PHARMACOLOGY IN 1977. British Journal of Clinical Pharmacology. 4(6). 667–668. 1 indexed citations

Hunter, K.R., et al.. (1976). CLINICAL PHARMACOLOGY. The Lancet. 307(7971). 1246–1247. 2 indexed citations

Hunter, K.R., et al.. (1975). Evaluation of once-daily versus twice-daily bumetanide in heart failure.. PubMed. 51 Suppl 6. 91–95. 3 indexed citations

Youdim, M.B.H., et al.. (1974). Enhanced tyramine conjugation in Parkinson's disease. Clinica Chimica Acta. 51(3). 327–329. 4 indexed citations

Sandler, M., Brian L. Goodwin, C.R.J. Ruthven, K.R. Hunter, & G M Stern. (1974). VARIATION OF LEVODOPA METABOLISM WITH GASTROINTESTINAL-ABSORPTION SITE. The Lancet. 303(7851). 238–240. 17 indexed citations

Wilkinson, Peter, et al.. (1974). Twice-Daily Propranolol Treatment for Hypertension. Journal of International Medical Research. 2(3). 220–223. 9 indexed citations

10.

Sandler, M., et al.. (1973). Tetrahydroisoquinoline Alkaloids: in vivo Metabolites of L-Dopa in Man. Nature. 241(5390). 439–443. 293 indexed citations

11.

Sandler, M., S. J. CORNE, RJ Stephens, et al.. (1972). METATYROSINE IN THE TREATMENT OF PARKINSONISM. The Lancet. 300(7777). 605–605. 5 indexed citations

12.

Whyte, R. K., K.R. Hunter, Laurence Després, G M Stern, & P. Armitage. (1971). Levodopa and orphenadrine hydrochloride in parkinsonism. European Journal of Clinical Pharmacology. 4(1). 18–21. 6 indexed citations

13.

Stern, G M & K.R. Hunter. (1971). Parkinsonism and the hypotension caused by l-dopa. American Heart Journal. 82(4). 570–572. 1 indexed citations

14.

Hunter, K.R., et al.. (1970). Neurological manifestations of hereditary haemorrhagic telangiectasis.. BMJ. 3(5724). 688–688. 12 indexed citations

15.

Hunter, K.R., A J Boakes, Laurence Després, & G M Stern. (1970). Monoamine oxidase inhibitors and L-dopa.. BMJ. 3(5719). 388–388. 51 indexed citations

16.

Hunter, K.R., G M Stern, Laurence Després, & P. Armitage. (1970). AMANTADINE IN PARKINSONISM. The Lancet. 295(7657). 1127–1129. 54 indexed citations

17.

Hunter, K.R., G M Stern, & Laurence Després. (1970). USE OF LEVODOPA WITH OTHER DRUGS. The Lancet. 296(7686). 1283–1285. 21 indexed citations

18.

Hunter, K.R., G M Stern, Laurence Després, & P. Armitage. (1970). COMBINED TREATMENT OF PARKINSONISM WITH L-DOPA AND AMANTADINE. The Lancet. 296(7672). 566–566. 13 indexed citations

19.

Hunter, K.R., et al.. (1970). LEVODOPA IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERS. The Lancet. 296(7684). 1186–1186. 25 indexed citations

20.

Hunter, K.R., G M Stern, & J A Sharkey. (1970). LEVODOPA IN POSTENCEPHALITIC PARKINSONISM. The Lancet. 296(7687). 1366–1367. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact